SCHEMBL6346387

SCHEMBL6346387

CCOC(=O)c1nn(-c2ccc(OOSN)cc2)c2c1CCc1ccc(N)cc1-2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 5/20 0.50
CDK2 P24941 5/20 0.50
CCNA1 P78396 5/20 0.50
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 4/20 0.43
HPGD P15428 2/20 0.43
TP53 P04637 1/20 0.43
ADORA1 P30542 5/20 0.40
MAPT P10636 3/20 0.40
HSD17B10 Q99714 2/20 0.40
APP P05067 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP6 P55212 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
PDE4D Q08499 1/20 0.39
RAD52 P43351 1/20 0.38
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
ALOX12 P18054 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5326432 0.88 CCNA2 (0.47) CCNA2CDK2CCNA1ALDH1A1KDM4E
SCHEMBL5253419 0.87 CCNA2 (0.46) CCNA2CDK2CCNA1F2F10
SCHEMBL6340632 0.85 ALDH1A1 (0.58) CCNA2CDK2CCNA1ALDH1A1KDM4E
SCHEMBL14532706 0.85 ALDH1A1 (0.54) CCNA2CDK2CCNA1ALDH1A1KDM4E
SCHEMBL14558176 0.83 CCNA2 (0.50) CCNA2CDK2CCNA1ALDH1A1KDM4E
SCHEMBL5254020 0.83 CCNA2 (0.50) CCNA2CDK2CCNA1ALDH1A1KDM4E
SCHEMBL6345072 0.80 ALDH1A1 (0.52) CCNA2CDK2CCNA1ALDH1A1KDM4E
SCHEMBL6658045 0.79 CCNA2 (0.46) CCNA2CDK2CCNA1F2F10
SCHEMBL5257996 0.76 CCNA2 (0.46) CCNA2CDK2CCNA1ALDH1A1KDM4E
SCHEMBL5336498 0.76 IKBKB (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849653-B2 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis PHARMACIA CORPORATION (US) 2005-02-01 US disclosed
EP-1438293-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2004-07-21 EP disclosed
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-07-03 US disclosed
WO-2003027075-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation IRAK4, NLRP3, CXCL8 CCNA2 2104/4885CDK2 372/4885CCNA1 1547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.